A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.

doi:10.1016/S2468-1253(21)00397-6

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.

The lancet. Gastroenterology & hepatology - 1 Apr 2022

Solomon Sunil S, Wagner-Cardoso Sandra, Smeaton Laura, Sowah Leonard A, Wimbish Chanelle, Robbins Gregory, Brates Irena, Scello Christine, Son Annie, Avihingsanon Anchalee, Linas Benjamin, Anthony Donald, Nunes Estevão Portela, Kliemann Dimas A, Supparatpinyo Khuanchai, Kityo Cissy, Tebas Pablo, Bennet Jaclyn Ann, Santana-Bagur Jorge, Benson Constance A, Van Schalkwyk Marije, Cheinquer Nelson, Naggie Susanna, Wyles David, Sulkowski Mark

Abstract excerpt

BACKGROUND: Despite widespread availability of direct-acting antivirals including generic formulations, limited progress has been made in the global adoption of hepatitis C virus (HCV) treatment. Barriers to treatment scale-up include availability and access to diagnostic and monitoring tests, health-care infrastructure, and requirement for frequent visits during treatment. METHODS: ACTG A5360 was a phase 4,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to RNA

Share to Sofosbuvir

Share to Treatment Outcome

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 35026142
DOI: 10.1016/S2468-1253(21)00397-6
PMCID: PMC8920770

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.PMID 35026142Read ↗

Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.Semantic proximity Read ↗

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.Semantic proximity Read ↗

Reinfection and Resistance Associated Substitutions Following a Minimal Monitoring Approach for Hepatitis C Virus Treatment in MINMON Trial.Semantic proximity Read ↗

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.Semantic proximity Read ↗

Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial).Semantic proximity Read ↗

Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.Semantic proximity Read ↗

Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort.Semantic proximity Read ↗

Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.Semantic proximity Read ↗

[Efficacy and tolerance of direct-acting antiviral drugs for the treatment of hepatitis C in Joseph Raseta Befelatanana Teaching Hospital in Antananarivo, Madagascar].Semantic proximity Read ↗

Feasability and effectiveness of scaling up hepatitis-C treatment in West and Central Africa: the TAC ANRS 12311 clinical trialSemantic proximity Read ↗

Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysisSemantic proximity Read ↗

Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.